stockrow
Friday 6 November 2026
Export DFTX’s income statement to Excel — free account
Definium Therapeutics, Inc.
DFTX Healthcare Biotechnology
- EPS
- −188.0%
- Free cash flow
- −78.3%
- Total debt
- −11.5%
Quarter to June 2026, against a year earlier
33.27
2.91
+9.58%
Follow DFTX
Alert me
Definium Therapeutics, Inc. (DFTX) Total debt
Definium Therapeutics, Inc.'s total debt at the end of fiscal 2025 was $40.6M, up 85.7% from $21.9M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $36.5M. Over the past ten years it has ranged from $12.6K (fiscal 2017) to $40.6M (fiscal 2025) — the current reading is the highest in ten years. Definium Therapeutics, Inc. ranks 148th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $40.6M | 85.68% |
| FY2024 | $21.9M | 54.67% |
| FY2023 | $14.1M | 26,391.88% |
| FY2022 | $53.3K | 324.63% |
| FY2017 | $12.6K | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $36.5M | (10.56%) |
| Mar 2026 | $40.8M | 0.48% |
| Dec 2025 | $40.6M | 0.48% |
| Sep 2025 | $40.4M | (1.96%) |
| 14 more quarters | Free account |
Against its own ten years
Low $12.6K
High $40.6M
Ten-year median
$14.1M
Current reading's percentile
100
Total debt against peers
| Company | Total debt |
|---|---|
| LEGN Legend Biotech Corporation Sponsored ADR compare | $156.4M |
| ABCL AbCellera Biologics Inc. compare | $81.0M |
| ERAS Erasca, Inc. compare | $56.8M |
| RLAY Relay Therapeutics, Inc. compare | $55.0M |
| ACAD ACADIA Pharmaceuticals Inc. compare | $48.1M |
| DFTX Definium Therapeutics, Inc. | $36.5M |
| XENE Xenon Pharmaceuticals Inc. compare | $11.0M |
| EWTX Edgewise Therapeutics, Inc. compare | $5.6M |
| DNTH Dianthus Therapeutics, Inc. compare | $670.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt